
Study Type: Treatment
https://www.facingourrisk.org/research-clinical-trials/study/425 /a-study-of-talazoparib-with-or-without-enzalutamide-in-people-with-prostate-cancer-who-have-previously-received-abiraterone-or-darolutamide-talent
Clinicaltrials.gov identifier:
NCT06844383 (https://clinicaltrials.gov/show/NCT06844383)
Treatment
Phase 2 study for metastatic castration-resistant prostate cancer with an HRR mutation
https://www.facingourrisk.org/research-clinical-trials/study/377 /an-new-targeted-therapy-cx5461-to-treat-advanced-breast-ovarian-pancreatic-or-prostate-cancer-with-inherited-or-tumor-mutations
Clinicaltrials.gov identifier:
NCT04890613 (https://clinicaltrials.gov/show/NCT04890613)
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
https://www.facingourrisk.org/research-clinical-trials/study/344 /study-looking-at-tumor-dna-to-predict-cancer-recurrence-for-those-planning-to-undergo-chemotherapy-for-high-risk-early-breast-cancer
Clinicaltrials.gov identifier:
NCT06401421 (https://clinicaltrials.gov/show/NCT06401421)
Treatment
Biomarker study for people with early-stage breast cancer
https://www.facingourrisk.org/research-clinical-trials/study/294 /high-dose-testosterone-treatment-for-people-with-metastatic-prostate-cancer-and-an-atm-cdk12-or-chek2mutation
Clinicaltrials.gov identifier:
NCT05011383 (https://clinicaltrials.gov/show/NCT05011383)
Treatment
People who have metastatic castration-resistant prostate cancer with an ATM, CDK12, or CHEK2 mutation
https://www.facingourrisk.org/research-clinical-trials/study/276 /study-of-colorectal-cancer-and-genetics-in-hispanic-and-latino-people-enlace-study
Treatment
Hispanic and Latino people diagnosed with colorectal cancer
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.